Isobolographic analysis of the ciprofloxacin-gentamicin combination against beta-lactamase-producing Staphylococcus aureus.
S. aureus
ciprofloxacin
drug interaction
gentamicin
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
01
06
2023
received:
22
03
2023
accepted:
09
06
2023
medline:
27
11
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
ppublish
Résumé
Bacterial multi-resistance is a serious global problem that continues to worsen over time due to multiple factors. Among these factors, it is important to highlight the clinical misuse of antibiotics and the mechanisms that microorganisms have developed to protect themselves from these drugs. In this sense, Staphylococcus aureus (S. aureus) is a pathogen that has found a way to resist many of the drugs currently in use, so infections by this bacterium represent a serious clinical problem. The purpose of this study was to determine the type of interaction between ciprofloxacin and gentamicin against beta-lactamase-producing S. aureus using isobolographic analysis. Ciprofloxacin (0.5-0.05 mg/mL) and gentamicin (10-1 mg/mL) were used to make concentration-dependent curves for each individual drug. Thereafter, the 50 inhibitory concentration (IC The isobolographic evaluation of the combination showed that the ratios 0.5:0.5, 0.8:0.2, 0.2:0.8, and 0.9:0.1 produced a synergistic anti-staphylococcal effect, and the 0.95:0.05 ratio induced an additive antibacterial effect. Finally, the 0.1:0.9 and 0.05:0.95 ratios of the combination presented antagonistic effects against S. aureus. On the other hand, the interaction index showed similar results to the isobolographic analysis. The isobolographic results of this in vitro assay show that the ciprofloxacin-gentamicin combination induces synergistic, additive, and antagonistic antimicrobial effects against S. aureus.
Sections du résumé
BACKGROUND
BACKGROUND
Bacterial multi-resistance is a serious global problem that continues to worsen over time due to multiple factors. Among these factors, it is important to highlight the clinical misuse of antibiotics and the mechanisms that microorganisms have developed to protect themselves from these drugs. In this sense, Staphylococcus aureus (S. aureus) is a pathogen that has found a way to resist many of the drugs currently in use, so infections by this bacterium represent a serious clinical problem.
OBJECTIVES
OBJECTIVE
The purpose of this study was to determine the type of interaction between ciprofloxacin and gentamicin against beta-lactamase-producing S. aureus using isobolographic analysis.
METHODS
METHODS
Ciprofloxacin (0.5-0.05 mg/mL) and gentamicin (10-1 mg/mL) were used to make concentration-dependent curves for each individual drug. Thereafter, the 50 inhibitory concentration (IC
RESULTS
RESULTS
The isobolographic evaluation of the combination showed that the ratios 0.5:0.5, 0.8:0.2, 0.2:0.8, and 0.9:0.1 produced a synergistic anti-staphylococcal effect, and the 0.95:0.05 ratio induced an additive antibacterial effect. Finally, the 0.1:0.9 and 0.05:0.95 ratios of the combination presented antagonistic effects against S. aureus. On the other hand, the interaction index showed similar results to the isobolographic analysis.
CONCLUSION
CONCLUSIONS
The isobolographic results of this in vitro assay show that the ciprofloxacin-gentamicin combination induces synergistic, additive, and antagonistic antimicrobial effects against S. aureus.
Substances chimiques
Ciprofloxacin
5E8K9I0O4U
Gentamicins
0
beta-Lactamases
EC 3.5.2.6
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1198-1204Informations de copyright
© 2023 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.
Références
Cheung GYC, Bae JS, Otto M. Pathogenicity and virulence of Staphylococcus aureus. Virulence. 2021;12(1):547-569. doi:10.1080/21505594.2021.1878688
McCaig LF, McDonald LC, Mandal S, Jernigan D. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12(11):1715-1723. doi:10.3201/eid1211.060190
Bouiller K, Hocquet D, Sauget M, Bertrand X, Chirouze C. Epidemiology and risk factors of Staphylococcus aureus CC398 bone and joint infections. BMC Infect Dis. 2020;20(1):384. doi:10.1186/s12879-020-05098-0
Lee AS, de Lencastre H, Garau J, et al. Methicillin-resistant Staphylococcus aureus. Nat Rev Dis Primers. 2018;4(1):18033. doi:10.1038/nrdp.2018.33
McGuinness WA, Malachowa N, De Leo FR. Vancomycin resistance in Staphylococcus aureus. Yale J Biol Med. 2017;90(2):269-281.
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
Cottarel G, Wierzbowski J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 2007;25(12):547-555. doi:10.1016/j.tibtech.2007.09.004
Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal. 2016;6(2):71-79. doi:10.1016/j.jpha.2015.11.005
Córdova-Guerrero I, Aragon-Martinez OH, Díaz-Rubio L, et al. Antibacterial and antifungal activity of Salvia apiana against clinically important microorganisms. Rev Argent Microbiol. 2016;48(3):217-221. doi:10.1016/j.ram.2016.05.007
Gómez-Sánchez E, Franco-de la Torre L, Hernández-Gómez A, et al. Antagonistic, synergistic, and additive antibacterial interaction between ciprofloxacin and amoxicillin against Staphylococcus aureus. Fundam Clin Pharmacol. 2023;37(1):174-181. doi:10.1111/fcp.12832
Tallarida RJ. Drug Synergism and Dose-effect Data Analysis. Chapman & Hall/CRC Press; 2000:26-131. doi:10.1201/9781420036107
Tallarida RJ. Combination analysis. Adv Exp Med Biol. 2010;678:133-137. doi:10.1007/978-1-4419-6306-2_17
Tallarida RJ. Drug combinations: tests and analysis with isoboles. Curr Protoc Pharmacol. 2016;72(1):9-19. doi:10.1002/0471141755.ph0919s72
Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002;98(1):163-168. doi:10.1016/S0304-3959(02)00041-6
Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman: Las bases farmacológicas de la terapéutica. 13ª Edición ed. McGraw-Hill; 2019.
Katzung BG, Vanderah TW. Farmacología Básica y Clínica. 5ª Edicióned. McGraw-Hill; 2022.
Bollenbach T. Antimicrobial interactions: mechanisms and implications for drug discovery and resistance evolution. Curr Opin Microbiol. 2015;27:1-9. doi:10.1016/j.mib.2015.05.008
Cantrell JM, Chung CH, Chandrasekaran S. Machine learning to design antimicrobial combination therapies: promises and pitfalls. Drug Discov Today. 2022;27(6):1639-1651. doi:10.1016/j.drudis.2022.04.006
Šíma M, Bobek D, Cihlářová P, et al. Factors affecting the metabolic conversion of ciprofloxacin and exposure to its main active metabolites in critically ill patients: population pharmacokinetic analysis of desethylene ciprofloxacin. Pharmaceutics. 2022;14(8):1627. doi:10.3390/pharmaceutics14081627
https://www.medicamentosplm.com/Home/productos/gentamicina_soluci%C3%B3n_inyectable/10/101/64803/162
Brunton LL, Hilala-Dandan R, Knollmann B. Goodman & Gilman. Las bases farmacológicas de la terapéutica. 13ª Edicióned. The McGraw-Hill Companies; 2018.
Pan Z, Fan L, Zhong Y, et al. Quantitative proteomics reveals reduction in central carbon and energy metabolisms contributes to gentamicin resistance in Staphylococcus aureus. J Proteomics. 2023;277:104849. doi:10.1016/j.jprot.2023.104849
Vestergaard M, Frees D, Ingmer H. Antibiotic resistance and the MRSA problem. Microbiol Spectr. 2019;7(2). doi:10.1128/microbiolspec